| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3328503 | Acta Haematologica Polonica | 2012 | 41 Pages |
Abstract
New drugs introduced in recent years to the therapy of multiple myeloma (MM) patients allow to obtain therapeutic responses in the majority of patients. Therapeutic regimens based on thalidomide and on bortezomib are recommended to the therapy as well of patients being candidates to high dose therapy and autologous stem cell transplantation as unfit to such procedure. In relapsed/refractory patients regimens based on lenalidomide are recommended. An integral part of MM therapy is maintenance therapy and supportive care. In this article we described also therapeutic recommendation for other plasmocytic dyscrasia.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Anna DmoszyÅska, Adam Walter-Croneck, Joanna MaÅko, Lidia Usnarska-Zubkiewicz, Beata Stella-HoÅowiecka, Jan Walewski, Grzegorz CharliÅski, WiesÅaw Wiktor JÄdrzejczak, Elżbieta Wiater, Ewa Lech-MaraÅda, Dominik Dytfeld, MieczysÅaw Komarnicki,